Chelsea Therapeutics International, Ltd. (NASDAQ: CHTP), a biopharmaceutical development company, is focused on acquiring and developing innovative products designed to treat a variety of human diseases. Currently, the company is developing a portfolio of metabolically inert antifolate compounds engineered to have potent anti-inflammatory and anti-tumor activity to treat a range of immunological disorders. Chelsea Therapeutics purposes to create value by building a world-class team, accelerating the development of its product candidates and expanding its therapeutic pipeline. For further information, visit the Company’s web site at www.chelseatherapeutics.com.
- 17 years ago
QualityStocks
Chelsea Therapeutics International, Ltd. (NASDAQ: CHTP)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – VolitionRx (NYSE American: VNRX) Prepares Reimbursement Submission for Nu.Q Cancer Assays in France
VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced that it is preparing a reimbursement submission for its Nu.Q®…
-
QualityStocksNewsBreaks – Brand Engagement Network Inc. (NASDAQ: BNAI) Reports Warrant Exercises, Debt Conversion, and Public Warrants Update
Brand Engagement Network Inc. (NASDAQ: BNAI) announced on Wednesday that it generated approximately $1.46 million…
-
Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape
The World Health Organization’s recent recognition of rare diseases as a global health priority underscores…